HPS Pharmacies wish to advise that Arrow Pharma, in consultation with the Therapeutic Goods Administration (TGA), is investigating a safety issue concerning:
Glyceryl Trinitrate 600µg Tablets
Anginine® ARTG 227783
Lycinate® ARTG 227784
The TGA is investigating reports of prolonged dissolution times and difficulty in breaking tablets. Glyceryl trinitrate tablets are administered sublingually for the treatment of acute angina pectoris. Prolonged dissolution may impact patient safety as adequate and timely pain relief may not be achieved.
These issues have only been identified in the new formulation of Anginine® and Lycinate®. These tablets may be distinguished by their round shape, while the old formulation is presented as square tablets.
No products are being recalled at this stage. It is important to note that Nitrolingual®, the spray-based formulation of glyceryl trinitrate, is not affected by this issue.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.